NASDAQ:ADXS - Advaxis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.25
  • Forecasted Upside: 336.89 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.52
▲ +0.01 (1.98%)

This chart shows the closing price for ADXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Advaxis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADXS

Analyst Price Target is $2.25
▲ +336.89% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Advaxis in the last 3 months. The average price target is $2.25, with a high forecast of $2.25 and a low forecast of $2.25. The average price target represents a 336.89% upside from the last price of $0.52.

This chart shows the closing price for ADXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Advaxis. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021Alliance Global PartnersLower Price TargetBuy$5.00 ➝ $2.25Medium
6/12/2019HC WainwrightReiterated RatingHold ➝ NeutralLow
4/5/2019HC WainwrightSet Price TargetHold$4.00Low
1/16/2019HC WainwrightReiterated RatingHoldHigh
12/18/2018HC WainwrightDowngradeBuy ➝ NeutralHigh
11/6/2018HC WainwrightSet Price TargetBuy$2.00High
9/12/2018HC WainwrightReiterated RatingBuyMedium
6/13/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$9.00 ➝ $2.00High
6/8/2018HC WainwrightReiterated RatingBuy$3.00Low
4/17/2018HC WainwrightReiterated RatingBuy$6.00High
3/14/2018HC WainwrightSet Price TargetBuy ➝ Buy$23.00 ➝ $6.00High
3/13/2018Cantor FitzgeraldLower Price TargetHold ➝ Overweight$19.00 ➝ $5.00High
12/28/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
12/27/2017HC WainwrightSet Price TargetBuy$23.00Medium
12/22/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
11/8/2017HC WainwrightReiterated RatingBuy$23.00N/A
9/25/2017Cantor FitzgeraldReiterated RatingBuy$19.00High
9/15/2017HC WainwrightReiterated RatingBuy$23.00Low
7/6/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
6/14/2017HC WainwrightSet Price TargetBuy$23.00Medium
6/12/2017Cantor FitzgeraldSet Price TargetBuy$19.00Medium
5/31/2017Cantor FitzgeraldReiterated RatingOverweight$19.00Medium
3/13/2017HC WainwrightSet Price TargetBuy$23.00Low
3/1/2017HC WainwrightReiterated RatingBuy$23.00N/A
2/27/2017Cantor FitzgeraldReiterated RatingBuy$19.00N/A
1/17/2017HC WainwrightSet Price TargetBuy$23.00N/A
11/29/2016Cantor FitzgeraldInitiated CoverageBuy$19.00N/A
10/25/2016HC WainwrightSet Price TargetBuy$23.00N/A
(Data available from 10/21/2016 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 11 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 7 very negative mentions
7/23/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/22/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Advaxis logo
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
Read More

Today's Range

Now: $0.52
Low: $0.50
High: $0.54

50 Day Range

MA: $0.48
Low: $0.39
High: $0.60

52 Week Range

Now: $0.52
Low: $0.26
High: $1.57

Volume

5,259,320 shs

Average Volume

10,218,086 shs

Market Capitalization

$75.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Advaxis?

The following equities research analysts have issued stock ratings on Advaxis in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for ADXS.

What is the current price target for Advaxis?

1 Wall Street analysts have set twelve-month price targets for Advaxis in the last year. Their average twelve-month price target is $2.25, suggesting a possible upside of 342.8%. Alliance Global Partners has the highest price target set, predicting ADXS will reach $2.25 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.25 for Advaxis in the next year.
View the latest price targets for ADXS.

What is the current consensus analyst rating for Advaxis?

Advaxis currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADXS will outperform the market and that investors should add to their positions of Advaxis.
View the latest ratings for ADXS.

How do I contact Advaxis' investor relations team?

Advaxis' physical mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company's listed phone number is (609) 452-9813 and its investor relations email address is [email protected] The official website for Advaxis is www.advaxis.com.